1[1]Sato T, Shoji H, Koga N. Endotoxin adsorption by polymyxin B immo bileized fiber column in patients with systemic inflammatory rssponse syndrome: The Japanese Experiense, Therapeutic Apheresis and Dialysis,2003,7(2) :252 - 258
2[2]Shoji H. Extracorporeal endotoxin removal for the treatment of sepsis:Endotoxin adsorption cartridge(Toraymyxin). Therapeutic Apheresis and Dialysis, 2003,7(1):108 - 114
3[3]Schmaldienst S, Banyai S, Stulnig TM, et al. Prospective randomised cross- over comparison of three LDL - apheresis system in stain pretreated patients with familial hypercholesterolaemia. Athernsclerosis,2000,151(2) :493 - 7
4[4]Ritter M. M, Parhofer K.G. Extracorporal low - density lipoprotein by innunoadsorption. Therapeutic Apheresis and Dialysis, 2003, 7 ( 3 ):370 - 372
5[5]Nakaji S, Haynshi N. Adsorption for myasthenia gravis treatment:Medisorba MG - 50. Therapeutic Apheresis and dialysis, 2003,7 ( 1 ):78 - 84
6[6]Hirata N, Kuriyama T, Yamawaki N. Immusorba TR and PH. Therapeutic Apheresis and Dialysis, 2003,7( 1 ) :85 - 90
7[7]Bambauer R,Schiel R, Latza R,et al. LDL apheresis in clinical practice: long - term treatment of severe hyperlipidemia. Ther Apher, 1997,1(1): 49-51
8[8]Brunton C, Varghese Z, Moorhead F. Lipoheresis in the nephrotic syndrome. kidney Int,1999,56(Suppl 71) :s6- s8
9[9]Yamamoto T,Yammashita T. Low - density lioprotein apheresis using the liposorber system: feature and clinical benefits. Ther Apher, 1998, 2(1) :25- 30
10[10]Bosch T, Keller C. Clinical effect of direct adorption of lipoprotein apheresis: Beyond cholesterol reduction. Therapeutic Apheresis and Dialysis, 2003, 7(3) :341 - 344
